Clinical Trials Directory

Trials / Completed

CompletedNCT00464620

Trial of Dasatinib in Advanced Sarcomas

A Phase II Trial of Dasatinib in Advanced Sarcomas

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
366 (actual)
Sponsor
Sarcoma Alliance for Research through Collaboration · Academic / Other
Sex
All
Age
13 Years
Healthy volunteers
Not accepted

Summary

This study will examine the response rate and the 6-month progression-free survival rates of subjects with advanced sarcoma treated with dasatinib.

Detailed description

Further details provided by SARC (Sarcoma Alliance for Research through Collaboration): Treatment: Subjects take Dasatinib twice daily by mouth for 28 days per 28 day cycle. Subjects will be seen for interim medical history, physical exam and laboratory studies prior to each cycle. Subjects will undergo tumor imaging every 2 months (8 weeks) for the first 6 months and approximately every 3 months thereafter while on treatment. A blood sample for collection of specimens with which to later study serum level of Dasatinib and effects on biomarkers of drug activity will be obtained approximately 2 to 4 weeks after the start of treatment. Central collection of archival tumor with which to later study the frequency of expression and/or mutation of kinases inhibited by dasatinib will occur. Subjects will be followed for approximately every 3 months until 2 years from registration and then approximately yearly until 5 years from registration.

Conditions

Interventions

TypeNameDescription
DRUGDasatiniboral agent, continuous dosing, Cycles = 28 days

Timeline

Start date
2007-05-01
Primary completion
2016-12-01
Completion
2017-05-01
First posted
2007-04-23
Last updated
2018-11-23
Results posted
2018-11-23

Locations

20 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00464620. Inclusion in this directory is not an endorsement.